Research programme: hepatitis C virus inhibitors - Dong Wha/XTL

Drug Profile

Research programme: hepatitis C virus inhibitors - Dong Wha/XTL

Alternative Names: HCV synthetic drug research programme - Dong Wha/XTL; Hepatitis C virus inhibitors research programme - Dong Wha/XTL

Latest Information Update: 15 Nov 2002

Price : $50

At a glance

  • Originator Dong Wha
  • Developer Dong Wha; XTL Biopharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Nov 2002 Discontinued - Preclinical for Hepatitis C in South Korea (unspecified route)
  • 15 Nov 2002 Discontinued - Preclinical for Hepatitis C in Israel (unspecified route)
  • 19 Jul 2002 HCV-Trimera disease model is available for licensing (http://www.xtlbio.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top